Growth Metrics

Bio-Techne (TECH) Income from Continuing Operations (2009 - 2026)

Bio-Techne's quarterly Income from Continuing Operations came in at 51047000.0 in Q1 2026, up 125.99% year-on-year from 22588000.0 in Q1 2025, and up 34.3% quarter-over-quarter from 38009000.0 in Q4 2025.

Bio-Techne has reported Income from Continuing Operations for 18 years, with the latest figure at 51047000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Income from Continuing Operations rose 125.99% year-over-year to 51047000.0; the trailing twelve-month figure through Mar 2026 stood at 22749000.0 (down 71.78% YoY), and the FY2025 full-year result was 13414000.0, down 111.46% from the prior year.
  • Income from Continuing Operations for Q1 2026 stood at 51047000.0, up from 38009000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 89734000.0 in Q3 2022, with the low at 104492000.0 in Q2 2025.
  • Average Income from Continuing Operations over 5 years is 35799352.94, with a median of 45685000.0 recorded in 2023.
  • Year-over-year, Income from Continuing Operations surged 193.98% in 2022 and tumbled 899.35% in 2025.
  • Tracing TECH's Income from Continuing Operations over 5 years: stood at 50005000.0 in 2022, then plunged by 45.08% to 27465000.0 in 2023, then climbed by 27.03% to 34890000.0 in 2024, then climbed by 8.94% to 38009000.0 in 2025, then surged by 34.3% to 51047000.0 in 2026.
  • The last three Income from Continuing Operations figures came in at 51047000.0 (Q1 2026), 38009000.0 (Q4 2025), and 38185000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -2.99 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -8.40 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -14.46 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.03 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -3.40 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 727.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 205.99 Mn
10 Bio-Techne 7.92 Bn 7.71 Bn 208.29 Mn 51.05 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 51.05 Mn
Dec 31, 2025 38.01 Mn
Sep 30, 2025 38.19 Mn
Jun 30, 2025 -104.49 Mn
Mar 31, 2025 22.59 Mn
Dec 31, 2024 34.89 Mn
Sep 30, 2024 33.60 Mn
Jun 30, 2024 -10.46 Mn
Mar 31, 2024 49.06 Mn
Dec 31, 2023 27.47 Mn
Sep 30, 2023 50.99 Mn
Jun 30, 2023 45.69 Mn
Mar 31, 2023 70.22 Mn
Dec 31, 2022 50.01 Mn
Sep 30, 2022 89.73 Mn
Jun 30, 2022 61.92 Mn
Mar 31, 2022 60.14 Mn
Dec 31, 2021 72.06 Mn
Sep 30, 2021 68.98 Mn
Jun 30, 2021 -65.88 Mn
Mar 31, 2021 45.40 Mn
Dec 31, 2020 46.14 Mn
Sep 30, 2020 33.40 Mn
Jun 30, 2020 72.45 Mn
Mar 31, 2020 36.43 Mn
Dec 31, 2019 119.62 Mn
Sep 30, 2019 14.40 Mn
Jun 30, 2019 16.46 Mn
Mar 31, 2019 44.65 Mn
Dec 31, 2018 17.56 Mn
Sep 30, 2018 17.40 Mn
Jun 30, 2018 -39.86 Mn
Mar 31, 2018 19.74 Mn
Dec 31, 2017 48.85 Mn
Sep 30, 2017 15.86 Mn
Jun 30, 2017 27.61 Mn
Mar 31, 2017 22.17 Mn
Dec 31, 2016 7.47 Mn
Sep 30, 2016 18.84 Mn
Jun 30, 2016 -4.04 Mn
Mar 31, 2016 30.29 Mn
Dec 31, 2015 25.85 Mn
Sep 30, 2015 22.71 Mn
Jun 30, 2015 29.66 Mn
Mar 31, 2015 24.29 Mn
Dec 31, 2014 33.21 Mn
Sep 30, 2014 23.91 Mn
Jun 30, 2014 -100.86 Mn
Mar 31, 2014 31.64 Mn
Dec 31, 2013 25.06 Mn
Sep 30, 2013 27.43 Mn
Jun 30, 2013 65.75 Mn
Mar 31, 2013 33.12 Mn
Dec 31, 2012 25.36 Mn
Sep 30, 2012 25.67 Mn
Jun 30, 2012 27.24 Mn
Mar 31, 2012 31.76 Mn
Dec 31, 2011 25.81 Mn
Sep 30, 2011 27.52 Mn
Jun 30, 2011 -102.75 Mn
Mar 31, 2011 31.06 Mn
Dec 31, 2010 26.53 Mn
Sep 30, 2010 26.37 Mn
Jun 30, 2010 -89.39 Mn
Mar 31, 2010 32.39 Mn
Dec 31, 2009 24.72 Mn
Sep 30, 2009 26.77 Mn